1341207-62-2
Chemical Structure
Pentixafor
- CAS No.: 1341207-62-2
- Formula:C60H80N14O14
- Molecular Weight:1221.36
IUPAC Name: 2,2',2''-(10-(2-((4-((3-((2R,5S,8S,14R)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-1-methyl-8-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)propyl)carbamoyl)benzyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
InChIKey: OSUJVKAXNLHVRB-HUMWUIFSSA-N
SMILES: O=C(NCC(N[C@@H](C1=O)CC(C=C2)=CC=C2O)=O)[C@@H](NC([C@@H](NC([C@H](N1C)CCCNC(C(C=C3)=CC=C3CNC(CN(CCN(CC4)CC(O)=O)CCN(CCN4CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)=O)CC5=CC(C=CC=C6)=C6C=C5
Biological Activity: Pentixafor is a cyclic pentapeptide ligand that targets CXCR4. Pentixafor is composed of the cyclic pentapeptide Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) (HY-P11451), a linker, and a DOTA chelator. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging[1][2][3][4]. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pentixafor | 99.60% | Pentixafor is a cyclic pentapeptide ligand that targets CXCR4. Pentixafor is composed of the cyclic pentapeptide Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) (HY-P11451), a linker, and a DOTA chelator. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging. Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Buck AK, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. [Content Brief]
- [2]. Schwarzenböck SM, et al. [68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression. Oncotarget. 2017 Sep 16;8(56):95606-95619. [Content Brief]
- [3]. Chen Z, et al. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease. Mini Rev Med Chem. 2023;23(7):787-803. [Content Brief]
- [4]. Poschenrieder A, et al. First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. Tomography. 2016 Jun;2(2):85-93. [Content Brief]
